As ER+ breast carcinoma responds better to chemotherapy, they postulated that ER- status and PD-L1+ expression in the tumor may lead to tumor evasion and may be considered a poor prognostic indicator for patients (21). The gene discussed is ESR1; the disease is neoplasm.